Eledon pharmaceuticals highlights recent business milestones and provides 2024 outlook

Reported updated data from ongoing phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated  dosed first participants in phase 2 bestow trial in kidney transplantation  tegoprubart dosed in second-ever pig to human xenotransplant procedure irvine, calif., jan. 04, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones.
ELDN Ratings Summary
ELDN Quant Ranking